176 related articles for article (PubMed ID: 21323105)
1. Development of nanosuspension formulation for oral delivery of quercetin.
Sun M; Gao Y; Pei Y; Guo C; Li H; Cao F; Yu A; Zhai G
J Biomed Nanotechnol; 2010 Aug; 6(4):325-32. PubMed ID: 21323105
[TBL] [Abstract][Full Text] [Related]
2. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
3. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
4. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Li H; Zhao X; Ma Y; Zhai G; Li L; Lou H
J Control Release; 2009 Feb; 133(3):238-44. PubMed ID: 18951932
[TBL] [Abstract][Full Text] [Related]
6. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.
Gao Y; Li Z; Sun M; Li H; Guo C; Cui J; Li A; Cao F; Xi Y; Lou H; Zhai G
Drug Dev Ind Pharm; 2010 Oct; 36(10):1225-34. PubMed ID: 20545506
[TBL] [Abstract][Full Text] [Related]
8. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
9. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
Hashem FM; Al-Sawahli MM; Nasr M; Ahmed OA
Drug Des Devel Ther; 2015; 9():3141-52. PubMed ID: 26150693
[TBL] [Abstract][Full Text] [Related]
10. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
11. Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability,
Gera S; Pooladanda V; Godugu C; Swamy Challa V; Wankar J; Dodoala S; Sampathi S
Pharm Dev Technol; 2020 Oct; 25(8):971-988. PubMed ID: 32403972
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vitro and in vivo evaluation of quercetin-loaded mixed micelles for oral delivery.
Lu Z; Bu C; Hu W; Zhang H; Liu M; Lu M; Zhai G
Biosci Biotechnol Biochem; 2018 Feb; 82(2):238-246. PubMed ID: 29327653
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of nanosuspension of quercetin with a miniaturized milling method].
Liu X; Liu J; Pang JY; Shen BD; Shen CY; Lian WQ; Li XF; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2984-2988. PubMed ID: 29139267
[TBL] [Abstract][Full Text] [Related]
14. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
15. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats.
Bagad M; Khan ZA
Int J Nanomedicine; 2015; 10():3921-35. PubMed ID: 26089668
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
[TBL] [Abstract][Full Text] [Related]
17. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity.
Jain S; Jain AK; Pohekar M; Thanki K
Free Radic Biol Med; 2013 Dec; 65():117-130. PubMed ID: 23792276
[TBL] [Abstract][Full Text] [Related]
18. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
19. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
20. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
